Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Apply
BMS-986016
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step